Israel Englander Spruce Biosciences, Inc. Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.7 - $5.49 $285,752 - $2.24 Million	-408,218 Reduced 79.97%	102,223 $80,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $2.93 $69,905 - $196,945	-67,217 Reduced 11.64%	510,441 $1.5 Million
Q2 2023 Aug 14, 2023	SELL	$1.92 - $2.6 $59,879 - $81,086	-31,187 Reduced 5.12%	577,658 $1.24 Million
Q1 2023 May 15, 2023	BUY	$1.15 - $3.17 $530,551 - $1.46 Million	461,349 Added 312.79%	608,845 $1.35 Million
Q4 2022 Feb 14, 2023	BUY	$0.99 - $1.43 $2,456 - $3,547	2,481 Added 1.71%	147,496 $162,000
Q3 2022 Nov 14, 2022	SELL	$1.18 - $2.19 $53,255 - $98,839	-45,132 Reduced 23.74%	145,015 $199,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $10.4M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.